Overweight Clinical Trials in Baltimore, Maryland

7 studies are recruiting for overweight in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

   The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which tre…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   PAREXEL Intl - EPCU-Baltimore, Baltimore, Maryland

   Locations

   2 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07566390 on ClinicalTrials.gov

2. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

   The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ascension Saint Agnes Heart Care, Baltimore, Maryland

   Locations

   50 in total

   Run by

   Pfizer

   See if you can join NCT07595549 on ClinicalTrials.gov

3. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

   The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

   Stage

   Phase 3

   Ages

   45 to 99

   Site

   Ascension Saint Agnes Heart Care, Baltimore, Maryland

   Locations

   783 in total

   Run by

   Amgen

   See if you can join NCT07037433 on ClinicalTrials.gov

4. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

   This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide …

   Stage

   Phase 3

   Ages

   8 to 18

   Site

   Barry J. Reiner, MD LLC, Baltimore, Maryland

   Locations

   121 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07253285 on ClinicalTrials.gov

5. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Johns Hopkins Children's Center, Baltimore, Maryland

   Locations

   117 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov

6. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

   The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MedStar Good Samaritan Hospital, Baltimore, Maryland

   Locations

   162 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07321886 on ClinicalTrials.gov

7. Night Owl Metabolism

   The proposed study uses a novel and rigorous randomized cross-over study design in youth (18-23y) with late and non-late chronotype (n=35 per group) to assess the glycemic effect of "aligning" an oral glucose tolerance test (OGTT) or first-meal of day to a subject's chronotype. Both groups will und…

   Stage

   Not phased

   Ages

   18 to 23

   Site

   Johns Hopkins School of Medicine, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT06507722 on ClinicalTrials.gov